EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy

Carien Carpenter, Nina Simmons, William J H Davis, Madeleine Thompson, Nico van Zandwijk iD, Catherine J Drummond, Glen Reid iD

International Journal of Molecular Sciences · 16.03.2026 · 27 (6) · 2701

DOI: 10.3390/ijms27062701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.03.2026. Verfasst von Carien Carpenter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, ErbB Receptors. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otago Innovation Limited, Royal Society of New Zealand Marsden Fund, University of Otago Master’s writing bursary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer deaths, with resistance to targeted therapies posing a major clinical challenge. Drug-tolerant persister (DTP) cells are key contributors to resistance, and targeting them offers new strategies to enhance existing treatments. MicroRNAs (miRNAs), particularly the tumour-suppressive miR-15/107 family, offer promise due to their ability to target multiple oncogenic pathways. This study evaluated a synthetic consensus miRNA mimic, conmiR-15/107, in NSCLC cell line models. Dose–response assays showed robust, dose-dependent growth inhibition in both EGFR-mutant (PC9) and KRAS-mutant (H358 and A549) lung adenocarcinoma cells, but not in the human bronchial epithelial cell line BEAS-2B. When combined with EGFR inhibitors (osimertinib and gefitinib) in PC9 cells, the mimics showed a higher rate of growth inhibition compared with the controls and reduced IC50 values. Similarly, conmiR-15/107 enhanced growth inhibition by the KRAS inhibitors sotorasib and adagrasib in H358 cells. RT-qPCR confirmed downregulation of conmiR-15/107 targets, including MEK1, BCL2 and BRCA1, suggesting a multi-target mechanism of action. Long-term assays showed that the mimics reduced the survival and delayed the proliferation of DTPs in osimertinib-treated PC9 cells as well as sotorasib-treated H358 cells. These findings support conmiR-15/107 as a potential adjunct to targeted therapy, capable of enhancing treatment efficacy and delaying resistance in lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLung NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsMolecular Targeted TherapyAntineoplastic AgentsTyrosine Kinase InhibitorsConsensus SequenceHumansDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)GefitinibPiperazinesPyridinesPyrimidinesAcetonitrilesCell Line, TumorTransfectionAcrylamidesAniline CompoundsIndoles

Stichwörter der Autor:innen

EGFRKRASdrug tolerancelung adenocarcinomamicroRNAtargeted therapy

Substanzen

MicroRNAsMIRN15 microRNA, humanMIRN107 microRNA, humanEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)osimertinibAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland 1142, New Zealand.
  • Sydney Local Health District, Sydney, NSW 2065, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.

ORCID-Profile: Nico van Zandwijk, Glen Reid

Förderung

  • Otago Innovation Limited
  • Royal Society of New Zealand Marsden Fund
  • University of Otago Master’s writing bursary
  • University of Otago Masters scholarship
  • PhD scholarship from the Cancer Research Trust of New Zealand

Zitieren

APA

Carpenter, C., Simmons, N., Davis, W. J. H., Thompson, M., Zandwijk, N. V., Drummond, C. J., & Reid, G. (2026). MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. International Journal of Molecular Sciences, 27(6), 2701. https://doi.org/10.3390/ijms27062701

Vancouver

Carpenter C, Simmons N, Davis WJH, Thompson M, Zandwijk NV, Drummond CJ, et al. MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. International Journal of Molecular Sciences. 2026;27(6):2701. doi:10.3390/ijms27062701

BibTeX
@article{Carpenter2026,
  author = {Carpenter, Carien and Simmons, Nina and Davis, William J H and Thompson, Madeleine and Zandwijk, Nico van and Drummond, Catherine J and Reid, Glen},
  title = {MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {2701},
  doi = {10.3390/ijms27062701}
}
Kostenlos starten →